Figure 5 | Scientific Reports

Figure 5

From: PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection

Figure 5

Comparison of improved discriminatory performance for each PD-L1 antibody using the time-dependent AUC graphs of RFS and DMFS. (a) Among the three PD-L1 antibodies, 22C3-IHC staining showed a higher AUC value in RFS. (b) Via addition to the null model in RFS, the improved AUC value based on the 22C3-IHC assay was observed to be superior among the three PD-L1 antibodies (AUC of 22C3 = 0.636, AUC of SP142 = 0.606, AUC of SP263 = 0.606). (c) Among the three PD-L1 antibodies, 22C3-IHC staining demonstrated a higher AUC value for DMFS. (d) Via addition to the null model in DMFS, the improved AUC value based on the 22C3-IHC assay was found to be superior among the three PD-L1 antibodies (AUC of 22C3 = 0.634, AUC of SP142 = 0.584, AUC of SP263 = 0.596).

Back to article page